Our results indicate that loss of Bcl-2 expression is correlated with a more aggressive behaviour of NSCLC tumors and high Bcl-2 expression defines a subgroup of patients with a favourable outcome. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.